Screening of anti-heart failure active compounds from fangjihuangqi decoction in verapamil-induced zebrafish model by anti-heart failure index approach
Open Access
- 7 October 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 999950
Abstract
Heart failure is the end stage of various cardiovascular diseases. Fangjihuangqi Decoction (FJHQD) is a famous traditional Chinese medicine (TCM) formula, which is clinically effective in the treatment of chronic heart failure. However, the anti-heart failure ingredients of FJHQD have not been clarified, and the related mechanisms of action are rarely studied. In the present study, through quantification analysis of heart rate and ventricular area changes, a heart failure model and cardiac function evaluation system in cardiomyocytes-labelled Tg (cmlc2: eGFP) transgenic zebrafish larvae were constructed, and the anti-heart failure index (AHFI) that can comprehensively evaluate the cardiac function of zebrafish was proposed. Based on this model, FJHQD, its mainly botanical drugs, components and ingredients were evaluated for the anti-heart failure effects. The results showed that FJHQD and its botanical drugs exhibited potent anti-heart failure activity. Furthermore, total alkaloids from Stephania tetrandra S. Moore, total flavonoids from Astragalus mongholicus Bunge and total flavonoids from Glycyrrhiza uralensis Fisch. ex DC. were identified to be the main components exerting the anti-heart failure activity of FJHQD. Then, we screened the main ingredients of these components, and glycyrrhizic acid, licochalcone A and calycosin were found to exhibit excellent cardioprotective effects. Finally, we found that FJHQD, glycyrrhizic acid, licochalcone A and calycosin may improve cardiac function in zebrafish by regulating oxidative stress, inflammatory response and apoptosis-related pathways. Taken together, our findings offer biological evidences toward the anti-heart failure effect of FJHQD, and provide guidance for the clinical application of FJHQD.Keywords
Funding Information
- National Key Research and Development Program of China (2018YFC1704502)
This publication has 40 references indexed in Scilit:
- Cardioprotective Effects of Glycyrrhizic Acid Against Isoproterenol-Induced Myocardial Ischemia in RatsInternational Journal of Molecular Sciences, 2011
- Oxidative Stress, Systemic Inflammation, and Severe PeriodontitisJournal of Dental Research, 2010
- High-resolution cardiovascular function confirms functional orthology of myocardial contractility pathways in zebrafishPhysiological Genomics, 2010
- High‐throughput screening and small animal models, where are we?British Journal of Pharmacology, 2010
- Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial InfarctionCirculation, 2008
- The Tol2kit: A multisite gateway‐based construction kit for Tol2 transposon transgenesis constructsDevelopmental Dynamics, 2007
- A Role for Caspase-1 in Heart FailureCirculation Research, 2007
- Role of Oxidative Stress in Cardiac Hypertrophy and RemodelingHypertension, 2007
- Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifyllineHeart, 2000
- A Prospective, Randomized, Controlled Trial of Prednisone for Dilated CardiomyopathyNew England Journal of Medicine, 1989